{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:34:13Z","timestamp":1792798453316,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.iac.2019.12.002","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T08:14:52Z","timestamp":1580112892000},"page":"329-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease"],"prefix":"10.1016","volume":"40","author":[{"given":"Kathleen","family":"Luskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiral","family":"Thakrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaci.2013.11.016","article-title":"Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"133","author":"Woessner","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2019.12.002_bib2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1081-1206(10)62084-4","article-title":"The natural history and clinical characteristics of aspirin-exacerbated respiratory disease","volume":"89","author":"Berges-Gimeno","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D2: A dominant mediator of aspirin exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2019.12.002_bib4","unstructured":"U.S. Department of Health & Human Services. Most recent asthma data. Centers for Disease Control and Prevention. <cdc.gov\/asthma\/most_recent_data.htm>"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib6","article-title":"Aspirin exacerbated respiratory disease: epidemiology, pathophysiology, and management","volume":"7","author":"Li","year":"2019","journal-title":"Med Sci (Basel)"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2500\/aap.2012.33.3541","article-title":"Aspirin-exacerbated respiratory disease: burden of disease","volume":"33","author":"Chang","year":"2012","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1513\/AnnalsATS.201703-259OC","article-title":"The economic burden of asthma in the United States, 2008-2013","volume":"15","author":"Nurmagambetov","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.anai.2010.05.009","article-title":"Impact of asthma control on sleep, attendance at work, normal activities, and disease burden","volume":"105","author":"Wertz","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.iac.2019.12.002_bib10","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1378\/chest.07-0713","article-title":"Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study","volume":"132","author":"Lee","year":"2007","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.iac.2019.12.002_bib11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/014556130708600715","article-title":"The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery","volume":"86","author":"Kim","year":"2007","journal-title":"Ear Nose Throat J"},{"issue":"242","key":"10.1016\/j.iac.2019.12.002_bib12","first-page":"1","article-title":"Summary health statistics for U.S. adults: National Health Interview Survey, 2008","author":"Pleis","year":"2009","journal-title":"Vital Health Stat 10"},{"issue":"5","key":"10.1016\/j.iac.2019.12.002_bib13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaip.2015.03.001","article-title":"Survey-defined patient experiences with aspirin-exacerbated respiratory disease","volume":"3","author":"Ta","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1067\/mai.2000.104548","article-title":"Alcoholic drinks: important triggers for asthma","volume":"105","author":"Vally","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2019.12.002_bib15","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/0091-6749(86)90261-7","article-title":"Red wine asthma: a controlled challenge study","volume":"78","author":"Dahl","year":"1986","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2019.12.002_bib16","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.rmed.2004.11.010","article-title":"Alcohol-induced upper airway symptoms: prevalence and co-morbidity","volume":"99","author":"Nihlen","year":"2005","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaip.2013.12.003","article-title":"Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease","volume":"2","author":"Cardet","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.iac.2019.12.002_bib18","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/alr.22168","article-title":"Alcohol-induced respiratory symptoms improve after aspirin desensitization in patients with aspirin-exacerbated respiratory disease","volume":"8","author":"Glicksman","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4 Pt 1","key":"10.1016\/j.iac.2019.12.002_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1164\/ajrccm.157.4.9707089","article-title":"Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics","volume":"157","author":"Dahl\u00e9n","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.iac.2019.12.002_bib20","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJMoa013508","article-title":"Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis","volume":"347","author":"Sousa","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1164\/ajrccm\/140.1.148","article-title":"Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma","volume":"140","author":"Arm","year":"1989","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"10.1016\/j.iac.2019.12.002_bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1034\/j.1399-3003.2000.15e09.x","article-title":"Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma","volume":"15","author":"Nizankowska","year":"2000","journal-title":"Eur Respir J"},{"issue":"3 Pt 1","key":"10.1016\/j.iac.2019.12.002_bib23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0091-6749(99)70324-6","article-title":"Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses","volume":"104","author":"Daffern","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1081-1206(10)62951-1","article-title":"Cromolyn sodium prevents bronchoconstriction and urinary LTE4 excretion in aspirin-induced asthma","volume":"80","author":"Yoshida","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.iac.2019.12.002_bib25","first-page":"1515","article-title":"Sodium cromoglycate nebulized solution has an acute bronchodilative effect in patients with aspirin-intolerant asthma (AIA)","volume":"41","author":"Imokawa","year":"1992","journal-title":"Arerugi"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jaci.2018.10.007","article-title":"Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease","volume":"143","author":"Cahill","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"22","key":"10.1016\/j.iac.2019.12.002_bib27","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1073\/pnas.1605957113","article-title":"Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99","volume":"113","author":"Bankova","year":"2016","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jaci.2018.08.008","article-title":"A\u00a0new spin on mast cells and cysteinyl leukotrienes: Leukotriene E4 activates mast cells in\u00a0vivo","volume":"142","author":"Bankova","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib29","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaci.2018.02.024","article-title":"Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor","volume":"142","author":"Lazarinis","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib30","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaci.2016.04.042","article-title":"Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease","volume":"138","author":"Feng","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib31","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaci.2013.05.008","article-title":"Prominent role of IFN-gamma in patients with aspirin-exacerbated respiratory disease","volume":"132","author":"Steinke","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2019.12.002_bib32","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jaip.2018.12.014","article-title":"Sinus surgery is associated with a decrease in aspirin-induced reaction severity in patients with aspirin exacerbated respiratory disease","volume":"7","author":"Jerschow","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"16","key":"10.1016\/j.iac.2019.12.002_bib33","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2011-10-384826","article-title":"Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes","volume":"119","author":"Laidlaw","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2016.11.023","article-title":"Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease","volume":"140","author":"Eastman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"16","key":"10.1016\/j.iac.2019.12.002_bib35","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1074\/jbc.C113.453704","article-title":"Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand","volume":"288","author":"Kanaoka","year":"2013","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib36","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/mol.56.3.657","article-title":"Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor","volume":"56","author":"Sarau","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.iac.2019.12.002_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/JAA.S88739","article-title":"Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances","volume":"9","author":"Steinke","year":"2016","journal-title":"J\u00a0Asthma Allergy"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1081-1206(10)61150-7","article-title":"The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease","volume":"95","author":"White","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.iac.2019.12.002_bib39","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1046\/j.1365-2745.2002.01501.x","article-title":"The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions","volume":"32","author":"Berges-Gimeno","year":"2002","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/ajrccm.165.1.2010080","article-title":"Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial","volume":"165","author":"Dahl\u00e9n","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1183\/09031936.04.00100303","article-title":"Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma","volume":"24","author":"Lee","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.iac.2019.12.002_bib42","series-title":"Anaphylaxis and hypersensitivity reactions","first-page":"116","article-title":"Anaphylaxis and hypersensitivity reactions","author":"White","year":"2019"},{"issue":"6","key":"10.1016\/j.iac.2019.12.002_bib43","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jaci.2005.07.027","article-title":"Efficacy and safety of mometasone furoate nasal spray in nasal polyposis","volume":"116","author":"Small","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/archoto.2009.2","article-title":"Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery","volume":"135","author":"Stj\u00e4rne","year":"2009","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"12","key":"10.1016\/j.iac.2019.12.002_bib45","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/lary.22396","article-title":"Postoperative care for Samter's triad patients undergoing endoscopic sinus surgery: a double-blinded, randomized controlled trial","volume":"121","author":"Rotenberg","year":"2011","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaci.2018.06.010","article-title":"NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis","volume":"143","author":"Leopold","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2019.12.002_bib47","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jaci.2009.09.018","article-title":"Pilot study of budesonide inhalant suspension irrigations for chronic eosinophilic sinusitis","volume":"124","author":"Steinke","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jaci.2018.06.001","article-title":"A\u00a0trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease","volume":"143","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0194599814555836","article-title":"Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study","volume":"152","author":"Sommer","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/alr.21678","article-title":"A\u00a0novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial","volume":"6","author":"Sommer","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib51","first-page":"302","article-title":"n-3 fatty acids and cysteinyl-leukotriene formation in humans in\u00a0vitro, ex\u00a0vivo, and in\u00a0vivo","volume":"121","author":"von Schacky","year":"1993","journal-title":"J\u00a0Lab Clin Med"},{"issue":"19","key":"10.1016\/j.iac.2019.12.002_bib52","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM198505093121903","article-title":"Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in\u00a0vitro neutrophil and monocyte leukotriene generation and neutrophil function","volume":"312","author":"Lee","year":"1985","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2019.12.002_bib53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.plefa.2018.03.004","article-title":"Omega-6 fatty acids and inflammation","volume":"132","author":"Innes","year":"2018","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib54","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaip.2017.10.011","article-title":"Dietary fatty acid modification for the treatment of aspirin-exacerbated respiratory disease: a prospective pilot trial","volume":"6","author":"Schneider","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2019.12.002_bib55","first-page":"448","article-title":"Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease","volume":"20","author":"Bobolea","year":"2010","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib56","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaip.2015.01.012","article-title":"Omalizumab in the treatment of aspirin-exacerbated respiratory disease","volume":"3","author":"Bergmann","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib57","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.iac.2019.12.002_bib58","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"13","key":"10.1016\/j.iac.2019.12.002_bib59","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.iac.2019.12.002_bib60","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.iac.2019.12.002_bib61","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib62","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A\u00a0retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib63","doi-asserted-by":"crossref","first-page":"AB8","DOI":"10.1016\/j.jaci.2016.12.081","article-title":"Efficacy of reslizumab in asthma patients with aspirin sensitivity and elevated blood eosinophils","volume":"139","author":"Katial RH","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2019.12.002_bib64","doi-asserted-by":"crossref","first-page":"4839230","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","volume":"2018","author":"Pelaia","year":"2018","journal-title":"Biomed Res Int"},{"issue":"26","key":"10.1016\/j.iac.2019.12.002_bib65","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib66","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.iac.2019.12.002_bib67","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2019.12.002_bib68","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1164\/ajrccm.151.5.7735581","article-title":"The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma","volume":"151","author":"Nasser","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib69","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jaci.2009.07.031","article-title":"Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization","volume":"124","author":"Steinke","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2019.12.002_bib70","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.rmed.2010.04.017","article-title":"Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge","volume":"104","author":"Kupczyk","year":"2010","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib71","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.193.2.255","article-title":"Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2","volume":"193","author":"Hirai","year":"2001","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib72","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jaci.2013.10.056","article-title":"Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells","volume":"133","author":"Xue","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib73","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1081-1206(10)61803-0","article-title":"Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"90","author":"Berges-Gimeno","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11882-008-0041-7","article-title":"The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis","volume":"8","author":"Williams","year":"2008","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib75","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1067\/mai.2003.7","article-title":"Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"111","author":"Berges-Gimeno","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1 Pt 1","key":"10.1016\/j.iac.2019.12.002_bib76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0091-6749(90)90222-P","article-title":"Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma","volume":"85","author":"Sweet","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib77","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0091-6749(96)70123-9","article-title":"Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes","volume":"98","author":"Stevenson","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2019.12.002_bib78","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2500\/ajr.2006.20.2913","article-title":"Medical and surgical considerations in patients with Samter's triad","volume":"20","author":"McMains","year":"2006","journal-title":"Am J Rhinol"},{"issue":"9","key":"10.1016\/j.iac.2019.12.002_bib79","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1398-9995.2008.01658.x","article-title":"Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300\u00a0mg aspirin daily","volume":"63","author":"Rozsasi","year":"2008","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib80","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/0194599814545750","article-title":"Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease","volume":"151","author":"Cho","year":"2014","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib81","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0091-6749(84)90361-0","article-title":"Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin","volume":"73","author":"Stevenson","year":"1984","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib82","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","article-title":"Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study","volume":"134","author":"Swierczynska-Krepa","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib83","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clim.2015.05.012","article-title":"Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial","volume":"160","author":"Esmaeilzadeh","year":"2015","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2019.12.002_bib84","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/all.12131","article-title":"Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease","volume":"68","author":"Fruth","year":"2013","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib85","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1034\/j.1399-3003.2000.016003432.x","article-title":"Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma","volume":"16","author":"Szczeklik","year":"2000","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib86","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaip.2015.01.007","article-title":"Tolerance of chronic low-dose aspirin does not preclude aspirin exacerbated respiratory disease","volume":"3","author":"Lee-Sarwar","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib87","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jaip.2018.10.019","article-title":"Aspirin desensitization: faster protocols for busy patients","volume":"7","author":"White","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib88","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00405-012-2048-x","article-title":"Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad","volume":"270","author":"Havel","year":"2013","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4168\/aair.2011.3.1.3","article-title":"Aspirin-exacerbated respiratory disease: evaluation and management","volume":"3","author":"Lee","year":"2011","journal-title":"Allergy Asthma Immunol Res"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib90","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11882-009-0023-4","article-title":"Aspirin sensitivity and desensitization for asthma and sinusitis","volume":"9","author":"Stevenson","year":"2009","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"10.1016\/j.iac.2019.12.002_bib91","doi-asserted-by":"crossref","first-page":"AB215","DOI":"10.1016\/j.jaci.2017.12.680","article-title":"Long-term follow-up of patients with aspirin-exacerbated respiratory disease status post-desensitization","volume":"141","author":"Do","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib92","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaci.2006.09.011","article-title":"Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease","volume":"119","author":"Lee","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib93","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaip.2016.11.021","article-title":"Plasma 15-hydroxyeicosatetraenoic acid predicts treatment outcomes in aspirin-exacerbated respiratory disease","volume":"5","author":"Jerschow","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2019.12.002_bib94","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000237254","article-title":"Incomplete aspirin desensitization in an aspirin-sensitive asthmatic","volume":"109","author":"Rothe","year":"1996","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"10.1016\/j.iac.2019.12.002_bib95","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1081-1206(10)60932-5","article-title":"Failure to maintain an aspirin-desensitized state in a patient with aspirin-exacerbated respiratory disease","volume":"97","author":"White","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2019.12.002_bib96","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jaci.2011.12.003","article-title":"Pancreatitis as a novel complication of aspirin therapy in patients with aspirin-exacerbated respiratory disease","volume":"129","author":"Hoyte","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2019.12.002_bib97","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jaci.2012.10.006","article-title":"Pancreatitis as a complication of aspirin desensitization for aspirin-exacerbated respiratory disease","volume":"131","author":"Durrani","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856119300931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856119300931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:44:19Z","timestamp":1760179459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856119300931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0889856119300931"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2019.12.002","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2019.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}